Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.

Imane Abou Dalle Hagop M KantarjianFarhad RavandiNaval G DaverXuemei WangElias J JabbourZeev EstrovCourtney D D DiNardoNaveen PemmarajuAlessandra FerrajoliNitin JainSa A WangNadya J JammalGautam BorthakurKiran NaqviSarah PelletierSherry PierceMichael AndreeffGuillermo Garcia ManeroJorge E CortesTapan Mahendra Kadia

Published in: Cancer (2021)

Lenalidomide is a safe and feasible maintenance strategy in patients with high-risk AML who are not candidates for ASCT, and it has beneficial effects for patients with negative measurable residual disease.

Keyphrases

acute myeloid leukemia
multiple myeloma
newly diagnosed
allogeneic hematopoietic stem cell transplantation
stem cell transplantation
chronic lymphocytic leukemia
open label
disease activity
systemic lupus erythematosus
clinical trial
double blind
low dose